Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS)
CONCLUSIONS
More-severe diabetes (defined by higher HbA1c and longer disease duration) but not prediabetes or less-severe diabetes was associated with smaller brain volumes and an increased burden of brain vascular pathology. No evidence was found that associations of diabetes with smaller brain volumes are mediated by brain vascular pathology, suggesting that other mechanisms may be responsible for these associations. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Schneider, A. L. C.; Selvin, E.; Sharrett, A. R.; Griswold, M.; Coresh, J.; Jack, C. R.; Knopman, D.; Mosley, T.; Gottesman, R. F. Tags: Epidemiology-Aging Epidemiology/Health Services Research Source Type: research
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
CONCLUSIONS
The nonspecific, long-acting sulfonylureas glyburide and glimepiride do not have an increased risk of cardiovascular adverse events compared with the specific, short-acting sulfonylureas gliclazide, glipizide, and tolbutamide. However, nonspecific, long-acting sulfonylureas glyburide and glimepiride have an increased risk of severe hypoglycemia. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Douros, A.; Yin, H.; Yu, O. H. Y.; Filion, K. B.; Azoulay, L.; Suissa, S. Tags: Epidemiology-Cardiovascular Disease Epidemiology/Health Services Research Source Type: research
Antihyperglycemic Medications: A Claims-Based Estimate of First-line Therapy Use Prior to Initialization of Second-line Medications
CONCLUSIONS
Despite published guidelines, second-line therapy often is initiated without evidence of recommended use of first-line therapy. Apparent treatment failures, which may in fact be attributable to nonadherence to guidelines, are common. Point-of-care and population-level processes are needed to monitor and improve guideline adherence. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Tseng, Y.-J.; Steinberg, G.; Fox, K. P.; Armstrong, J.; Mandl, K. D. Tags: Epidemiology-Other Epidemiology/Health Services Research Source Type: research
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
CONCLUSIONS
The findings suggest that incident dysglycemia without Index60 ≥1.00 is a suboptimal prediagnostic end point for type 1 diabetes. Measures that include both glucose and C-peptide levels, such as Index60 ≥1.00, appear better suited as prediagnostic end points. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Nathan, B. M.; Boulware, D.; Geyer, S.; Atkinson, M. A.; Colman, P.; Goland, R.; Russell, W.; Wentworth, J. M.; Wilson, D. M.; Evans-Molina, C.; Wherrett, D.; Skyler, J. S.; Moran, A.; Sosenko, J. M.; the Type 1 Diabetes TrialNet and Diabetes Prevention T Tags: Epidemiology-Type 1 Diabetes Epidemiology/Health Services Research Source Type: research
Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study
CONCLUSIONS
Diabetes of the exocrine pancreas is frequently labeled type 2 diabetes but has worse glycemic control and a markedly greater requirement for insulin. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Woodmansey, C.; McGovern, A. P.; McCullough, K. A.; Whyte, M. B.; Munro, N. M.; Correa, A. C.; Gatenby, P. A. C.; Jones, S. A.; de Lusignan, S. Tags: Epidemiology-Clinical-Diagnosis and Screening Epidemiology/Health Services Research Source Type: research
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
CONCLUSIONS
Our findings do not suggest an increased risk of AKI associated with SGLT2 inhibitor use in patients with T2D in two large health systems. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Nadkarni, G. N.; Ferrandino, R.; Chang, A.; Surapaneni, A.; Chauhan, K.; Poojary, P.; Saha, A.; Ferket, B.; Grams, M. E.; Coca, S. G. Tags: Epidemiology-Other Epidemiology/Health Services Research Source Type: research
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes
CONCLUSIONS
Poor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Carls, G. S.; Tuttle, E.; Tan, R.-D.; Huynh, J.; Yee, J.; Edelman, S. V.; Polonsky, W. H. Tags: Epidemiology/Health Services Research Source Type: research
Cut Points for Identifying Clinically Significant Diabetes Distress in Adolescents With Type 1 Diabetes Using the PAID-T: Results From Diabetes MILES Youth-Australia
CONCLUSIONS
Using the PAID-T, this study defined two clinically meaningful cut points to distinguish none-to-mild, moderate, and high diabetes distress in adolescents (aged 13–19). Based on these cut points, most respondents experienced at least moderate diabetes distress, which was clinically significant. Establishing thresholds for elevated diabetes distress will aid clinicians and researchers to interpret PAID-T scores, prompt discussion and intervention for those with unmet needs, and enable the effectiveness of interventions to be evaluated. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Hagger, V.; Hendrieckx, C.; Cameron, F.; Pouwer, F.; Skinner, T. C.; Speight, J. Tags: Psychosocial, Behavioral Medicine Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
What End Users and Stakeholders Want From Automated Insulin Delivery Systems
CONCLUSIONS
Incorporating stakeholder perspectives on use of automated insulin delivery systems will improve the adoption of devices, quality of life, and likelihood of optimal health. Efforts to build trust in systems, optimize user-system interactions, and provide clear guidance about device capabilities and limitations may help potential users achieve optimal glycemic outcomes. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Naranjo, D.; Suttiratana, S. C.; Iturralde, E.; Barnard, K. D.; Weissberg-Benchell, J.; Laffel, L.; Hood, K. K. Tags: Clinical Therapeutics/New Technology-Insulin Delivery Systems Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
Effect of a Behavioral Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle: The Italian Diabetes and Exercise Study 2 (IDES_2): A Randomized Controlled Trial
CONCLUSIONS
This behavioral intervention is effective in the short term for increasing LPA and MVPA and reducing SED-time. Significant improvements in cardiometabolic risk profiles were observed in subjects experiencing the most pronounced changes in PA and SED-time, even if below the recommended level. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Balducci, S.; DErrico, V.; Haxhi, J.; Sacchetti, M.; Orlando, G.; Cardelli, P.; Vitale, M.; Bollanti, L.; Conti, F.; Zanuso, S.; Nicolucci, A.; Pugliese, G.; for the Italian Diabetes and Exercise Study 2 (IDES{-}_2) Investigators Tags: Exercise Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
Diabetes, Associated Clinical Spectrum, Long-term Prognosis, and Genotype/Phenotype Correlations in 201 Adult Patients With Hepatocyte Nuclear Factor 1B (HNF1B) Molecular Defects
CONCLUSIONS
In patients with HNF1B syndrome, diabetes complications, cardiovascular risk factors, CKD3–4, and ESRD are highly prevalent. At diabetes diagnosis, the presence of morphological and/or functional kidney disease may help etiological diagnosis. Genotype/phenotype correlations may have implications for the care and the prognosis of these patients. (Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Dubois-Laforgue, D.; Cornu, E.; Saint-Martin, C.; Coste, J.; Bellanne-Chantelot, C.; Timsit, J.; for the Monogenic Diabetes Study Group of the Societe Francophone du Diabete Tags: Clinical Care/Education/Nutrition/Psychosocial Research Source Type: research
The Promise and Practice of Genetics on Diabetes Care: The Fog Rises to Reveal a Field of Genetic Complexity in HNF1B
(Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Rich, S. S. Tags: Genetics-Type 1 Diabetes Commentary Source Type: research
Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control
Despite U.S. Food and Drug Administration (FDA) approval of over 40 new treatment options for type 2 diabetes since 2005, the latest data from the National Health and Nutrition Examination Survey show that the proportion of patients achieving glycated hemoglobin (HbA1c) <7.0% (<53 mmol/mol) remains around 50%, with a negligible decline between the periods 2003–2006 and 2011–2014. The Healthcare Effectiveness Data and Information Set reports even more alarming rates, with only about 40% and 30% of patients achieving HbA1c <7.0% (<53 mmol/mol) in the commercially insured (HMO) and Medicaid populations...
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Edelman, S. V.; Polonsky, W. H. Tags: Epidemiology-Other Perspectives in Care Source Type: research
In This Issue of Diabetes Care
(Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Tags: In This Issue Source Type: research
Response to Comment on Craig et al. Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. Diabetes Care 2017;40:1034-1040
(Source: Diabetes Care)
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Craig, M. E.; Prinz, N.; Boyle, C. T.; Campbell, F. M.; Jones, T. W.; Hofer, S. E.; Simmons, J. H.; Holman, N.; Tham, E.; Fröhlich-Reiterer, E.; DuBose, S.; Thornton, H.; King, B.; Maahs, D. M.; Holl, R. W.; Warner, J. T.; on behalf of the Austral Tags: Pediatrics-Type 1 Diabetes e-Letters: Comments and Responses Source Type: research
